Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 88.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 871,527 shares of the company’s stock after purchasing an additional 409,357 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Ventyx Biosciences were worth $1,909,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. State Street Corp grew its position in Ventyx Biosciences by 0.8% in the 3rd quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after buying an additional 9,783 shares during the last quarter. Catalina Capital Group LLC purchased a new position in Ventyx Biosciences during the 4th quarter worth $25,000. Palumbo Wealth Management LLC lifted its stake in shares of Ventyx Biosciences by 97.1% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock worth $52,000 after acquiring an additional 11,792 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Ventyx Biosciences by 3.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,101 shares of the company’s stock valued at $1,058,000 after acquiring an additional 17,898 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Ventyx Biosciences during the third quarter worth about $42,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $1.37 on Wednesday. The company has a market cap of $97.45 million, a P/E ratio of -0.58 and a beta of 0.58. Ventyx Biosciences, Inc. has a one year low of $1.33 and a one year high of $8.02. The business has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.09.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.13. Sell-side analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Insider Transactions at Ventyx Biosciences

In other news, insider John Nuss sold 13,161 shares of Ventyx Biosciences stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the completion of the transaction, the insider now owns 485,701 shares of the company’s stock, valued at $1,097,684.26. The trade was a 2.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Sheila Gujrathi acquired 130,000 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the transaction, the director now directly owns 130,000 shares in the company, valued at approximately $300,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 18.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.